Individual Patient Data Meta-analysis on Prehospital Risk Assessment in Patients Suspected of Non-ST-segment Elevation Acute Coronary Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Pieter-Jan Vlaar, MD, PhD
- Phone Number: 040 239 9111
- Email: pieter-jan.vlaar@catharinaziekenhuis.nl
Study Locations
-
-
-
Eindhoven, Netherlands
- Catharina Hospital Eindhoven
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients suspected for NSTE-ACS;
- Prospective study
- Original data
- Presenting prehospital (EMS)
- Prehospital risk assessment using at least POC-troponin, performed and analyzed by EMS.
- Outcome data available on in-hospital ACS or MACE within 30 days.
Exclusion Criteria:
- Enrolling only a specific subpopulation from the general ACS population
- Studies with less than 100 patients
- Studies enrolling only patients with STEMI.
- Studies published before 1995 / the pre-troponin era
- Studies performed by general practitioners.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Usual care
Patients who receive usual care by EMS protocols
|
Prehospital risk stratification by EMS protocols
|
|
Other: point-of-care troponin
Patients in who risk-stratification was performed by the use of a point-of-care troponin in the EMS setting
|
Prehospital risk stratification by the use of a POC-troponin
|
|
Other: Combined risk scores
Patients in who risk-stratification was performed by the use of a combined risk score in the EMS setting
|
Prehospital risk stratification by the use of a combined clinical risk score including POC-troponin
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with the diagnosis NSTE-ACS
Time Frame: During index hospitalization, up to 1 day in the ED
|
Diagnosis of NSTE-ACS (NSTEMI or unstable AP) during index hospitalization (as assessed by the treating physician)
|
During index hospitalization, up to 1 day in the ED
|
|
MACE
Time Frame: Within 30 days
|
All cause death, myocardial infarction, revascularization
|
Within 30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MACE
Time Frame: 1 week
|
All cause death, myocardial infarction, revascularization
|
1 week
|
|
All cause death
Time Frame: Within 30 days and 1 year follow-up
|
Within 30 days and 1 year follow-up
|
|
|
The number of participants undergoing invasive coronary angiography
Time Frame: During or after index hospitalisation, up to 30 days
|
During or after index hospitalisation, up to 30 days
|
|
|
The number of participants undergoing coronary revascularisation
Time Frame: During or after index hospitalisation, up to 30 days
|
percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
|
During or after index hospitalisation, up to 30 days
|
|
Alternative diagnoses other than NSTE-ACS
Time Frame: during 30 day follow-up after inclusion
|
If no NSTE-ACS is diagnosed, what is the alternative diagnosis (such as pulmonary embolism, aortic dissection, pneumothorax)
|
during 30 day follow-up after inclusion
|
|
Safety endpoints concerning intracoronary angiography and/or PCI
Time Frame: during 30 day follow-up after intracoronary angiography and/or PCI
|
Bleeding complications
|
during 30 day follow-up after intracoronary angiography and/or PCI
|
|
Safety endpoints concerning intracoronary angiography and/or PCI
Time Frame: during 30 day follow-up after intracoronary angiography and/or PCI
|
Contrast-induced nephropathy Possible or definite stent thrombosis Ischemic stroke Death
|
during 30 day follow-up after intracoronary angiography and/or PCI
|
|
Safety endpoints concerning intracoronary angiography and/or PCI
Time Frame: during 30 day follow-up after intracoronary angiography and/or PCI
|
Possible or definite stent thrombosis
|
during 30 day follow-up after intracoronary angiography and/or PCI
|
|
Safety endpoints concerning intracoronary angiography and/or PCI
Time Frame: during 30 day follow-up after intracoronary angiography and/or PCI
|
Ischemic stroke
|
during 30 day follow-up after intracoronary angiography and/or PCI
|
|
Safety endpoints concerning intracoronary angiography and/or PCI
Time Frame: during 30 day follow-up after intracoronary angiography and/or PCI
|
Death
|
during 30 day follow-up after intracoronary angiography and/or PCI
|
|
Health care utilization
Time Frame: Within 30 days after inclusion
|
Number of ambulance transfers
|
Within 30 days after inclusion
|
|
Health care utilization
Time Frame: Up to 30 days after inclusion
|
Duration of hospitalisation (days)
|
Up to 30 days after inclusion
|
|
Health care utilization
Time Frame: Within 30 days after inclusion
|
Number of double invasive coronary angiography procedures
|
Within 30 days after inclusion
|
|
Total health care costs
Time Frame: At 30 days
|
At 30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Pieter-Jan Vlaar, MD, PhD, Catharina Ziekenhuis Eindhoven
Publications and helpful links
General Publications
- Sagel D, Vlaar PJ, van Roosmalen R, Waardenburg I, Nieuwland W, Lettinga R, van Barneveld R, Jorna E, Kijlstra R, van Well C, Oomen A, Bartels L, Anthonio R, Hagens V, Hofma S, Gu Y, Drenth D, Addink R, van Asselt T, van der Meer P, Lipsic E, Juarez Orozco L, van der Harst P. Prehospital risk stratification in patients with chest pain. Emerg Med J. 2021 Nov;38(11):814-819. doi: 10.1136/emermed-2020-210212. Epub 2021 Aug 9.
- Demandt JPA, Zelis JM, Koks A, Smits GHJM, van der Harst P, Tonino PAL, Dekker LRC, van Het Veer M, Vlaar PJ. Prehospital risk assessment in patients suspected of non-ST-segment elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ Open. 2022 Apr 5;12(4):e057305. doi: 10.1136/bmjopen-2021-057305.
- Camaro C, Aarts GWA, Adang EMM, van Hout R, Brok G, Hoare A, Rodwell L, de Pooter F, de Wit W, Cramer GE, van Kimmenade RRJ, Damman P, Ouwendijk E, Rutten M, Zegers E, van Geuns RM, Gomes MER, van Royen N. Rule-out of non-ST-segment elevation acute coronary syndrome by a single, pre-hospital troponin measurement: a randomized trial. Eur Heart J. 2023 May 14;44(19):1705-1714. doi: 10.1093/eurheartj/ehad056.
- Tolsma RT, Fokkert MJ, van Dongen DN, Badings EA, van der Sluis A, Slingerland RJ, van 't Riet E, Ottervanger JP, van 't Hof AWJ. Referral decisions based on a pre-hospital HEART score in suspected non-ST-elevation acute coronary syndrome: final results of the FamouS Triage study. Eur Heart J Acute Cardiovasc Care. 2022 Feb 8;11(2):160-169. doi: 10.1093/ehjacc/zuab109.
- Demandt JPA, Koks A, Haest R, Heijmen E, Thijssen E, Otterspoor LC, van Veghel D, El Farissi M, Eerdekens R, Vervaat F, Pijls NHJ, Veer MVT, Tonino PAL, Dekker LRC, Vlaar PJ. Prehospital triage of patients with suspected non-ST-segment elevation acute coronary syndrome: Rationale and design of the TRIAGE-ACS study. Contemp Clin Trials. 2022 Aug;119:106854. doi: 10.1016/j.cct.2022.106854. Epub 2022 Jul 18.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- nWMO-2023.086
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.